Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 1Active not recruiting 1

Sponsor Class

OTHER 111NIH 12INDUSTRY 11OTHER_GOV 4NETWORK 2UNKNOWN 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 2

Conditions

Ovarian Neoplasms 1Ovarian Cancer Prevention 1

Interventions

Radiotherapy 302Cisplatin 266Cyclophosphamide 230Doxorubicin 177Paclitaxel 170Vincristine 162Carboplatin 152Filgrastim 140Etoposide 139Gemcitabine 118Docetaxel 114Fluorouracil 113Methotrexate 106Dexamethasone 106Cytarabine 106Prednisone 92Leucovorin 90Gene Expression Profiling 82Granulocyte Colony-Stimulating Factor 75Specimen Handling 70Magnetic Resonance Spectroscopy 63Irinotecan 59Capecitabine 59Radiation 54Polymerase Chain Reaction 51Ifosfamide 51Rituximab 49Immunohistochemistry 49Daunorubicin 49Oxaliplatin 48

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
NETWORK × Aspirin × Clear all
NCT03480776 2026-01-14

ASA in Prevention of Ovarian Cancer (STICs and STONEs)

Canadian Cancer Trials Group

Phase 2 Active not recruiting
117 enrolled
Gynecologic

Ovarian Cancer Prevention

NCT02659384 2023-03-14

Anti-programmed Cell Death-1 Ligand 1 (aPDL-1) Antibody Atezolizumab, Bevacizumab and Acetylsalicylic Acid in Recurrent Platinum Resistant Ovarian Cancer

European Organisation for Research and Treatment of Cancer - EORTC

Phase 2 Completed
122 enrolled
Gynecologic

Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡